UPC Analytics
DEEN
Übersicht · Eingereicht: 22. Jan. 2025

UPC_CFI_40/2025

TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT

Prozessuale & UnteranträgeKostenfestsetzungenHamburg LDGenericCase Closed
ÜbersichtEntscheidungenDokumenteZeitverlauf
Parteien

Kläger

  • Samsung Bioepis NL B.V.
Vertreter: Elena Hennecke (Freshfields PartG mbB)

Beklagte

Vertreter: Andrea Ritter (Simmons & Simmons LLP)
Richter
  • Sabine Klepsch
  • Alima Zana
  • Stefan Schilling
  • Rudi Goedeweeck
Patente
  • EP3167888
  • EP 3 167 888
CPC-Codes: A61P31/04, A61P25/18, A61P29/02, A61K39/395, A61K2039/505, A61P7/02, A61P25/26, A61P13/02, A61P15/10, A61P17/00, A61P7/00, A61P25/28…

Sektor: Organic Chemistry

Ausgang
Nur Kosten
Eingereicht: 22. Jan. 2025
Erste Entscheidung: —
Sprache: —

Decision of Hamburg Local Division in Samsung Bioepis NL B.V. v Alexion Pharmaceuticals (EP 3 167 888) assessing the costs of appeal proceedings following the Court of Appeal's rejection (20 December 2024) of Alexion's appeal against the dismissal of its application for provisional measures against Samsung Bioepis' Epysqli biosimilar. The court allowed the costs for UPC representatives and patent attorneys but reduced costs claimed for UK solicitors whose involvement (at higher cost than the actual UPC representatives) was not demonstrated to be necessary.

Im UPC-Register öffnen